ZA200807800B - Use of N-(dibenz (B,F) oxepin-10-ylmethyl) N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of congenital muscular dystrophy or myopathy resulting from collagen VI deficiency - Google Patents

Use of N-(dibenz (B,F) oxepin-10-ylmethyl) N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of congenital muscular dystrophy or myopathy resulting from collagen VI deficiency

Info

Publication number
ZA200807800B
ZA200807800B ZA200807800A ZA200807800A ZA200807800B ZA 200807800 B ZA200807800 B ZA 200807800B ZA 200807800 A ZA200807800 A ZA 200807800A ZA 200807800 A ZA200807800 A ZA 200807800A ZA 200807800 B ZA200807800 B ZA 200807800B
Authority
ZA
South Africa
Prior art keywords
prophylaxis
collagen
treatment
omigapil
ynylamine
Prior art date
Application number
ZA200807800A
Other languages
English (en)
Inventor
Meier Thomas
Original Assignee
Santhera Pharmaceuticals Ch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santhera Pharmaceuticals Ch filed Critical Santhera Pharmaceuticals Ch
Publication of ZA200807800B publication Critical patent/ZA200807800B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
ZA200807800A 2006-04-05 2008-09-10 Use of N-(dibenz (B,F) oxepin-10-ylmethyl) N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of congenital muscular dystrophy or myopathy resulting from collagen VI deficiency ZA200807800B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06007217A EP1842539A1 (fr) 2006-04-05 2006-04-05 Utilisation de N-(dibenz(b,f)oxepin-10-ylmethyl)N-methyl-N-prop-2-ynylamine (omigapil) pour la prévention et/ou le traitement de la dystrophie musculaire congénitale ou de la myopathie résultant d'un manque de collagène IV

Publications (1)

Publication Number Publication Date
ZA200807800B true ZA200807800B (en) 2009-06-24

Family

ID=36190429

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200807800A ZA200807800B (en) 2006-04-05 2008-09-10 Use of N-(dibenz (B,F) oxepin-10-ylmethyl) N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of congenital muscular dystrophy or myopathy resulting from collagen VI deficiency

Country Status (16)

Country Link
US (1) US7875648B2 (fr)
EP (2) EP1842539A1 (fr)
JP (1) JP4972156B2 (fr)
AT (1) ATE530181T1 (fr)
AU (1) AU2007236161B2 (fr)
CA (1) CA2648155C (fr)
CY (1) CY1112132T1 (fr)
DK (1) DK2004176T3 (fr)
ES (1) ES2371627T3 (fr)
MX (1) MX2008012867A (fr)
NZ (1) NZ571129A (fr)
PL (1) PL2004176T3 (fr)
PT (1) PT2004176E (fr)
SI (1) SI2004176T1 (fr)
WO (1) WO2007115776A1 (fr)
ZA (1) ZA200807800B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1757284A1 (fr) * 2005-08-25 2007-02-28 Santhera Pharmaceuticals (Schweiz) AG Utilisation de la N-(dibenz(b,f)oxepin-10ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) pour la prévention ou le traitement de la dystrophie musculaire
WO2014120885A1 (fr) 2013-01-30 2014-08-07 The Johns Hopkins University Traitement d'abus de drogues par prévention de la nitrosylation de la gadph
WO2022258629A1 (fr) 2021-06-07 2022-12-15 Katholieke Universiteit Leuven Idébénone dans le traitement de l'épilepsie pharmacorésistante

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780244A (en) * 1993-09-27 1998-07-14 La Jolla Cancer Research Foundation Changes in laminin subunit composition are diagnostic of Fukuyama congenital muscular dystrophy
US5863743A (en) * 1994-08-12 1999-01-26 University Of Iowa Research Foundation Merosin deficiency-type congenital muscular dystrophy
EP0726265B1 (fr) * 1995-02-08 2001-07-25 Novartis AG 10-Aminoaliphatyl-dibenz(b,f)oxépines avec une activité antineurodégénérative
AR008371A1 (es) * 1996-05-30 2000-01-19 Novartis Ag Una sal de adicion con acido de una 10-aminoalifatil-dibenz[b,f],oxepina, su empleo; procedimiento para su elaboracion, una 10-aminoalifatil-dibenz[b,f]oxepina, una preparacion farmaceutica que contiene dicha sal o dicha oxepina y un procedimiento para el tratamiento de enfermedades neurodegenerativ
US7078379B2 (en) * 2002-06-03 2006-07-18 Santhera Pharmaceuticals (Schweiz) Gmbh Treatment of congenital muscular dystrophies
TW200505435A (en) 2003-01-29 2005-02-16 Novartis Ag Treatment of ocular disorders
AR046320A1 (es) 2003-11-06 2005-11-30 Novartis Ag Composiciones farmaceuticas estabilizadas de dibenzo-oxepina.
EP1757284A1 (fr) 2005-08-25 2007-02-28 Santhera Pharmaceuticals (Schweiz) AG Utilisation de la N-(dibenz(b,f)oxepin-10ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) pour la prévention ou le traitement de la dystrophie musculaire

Also Published As

Publication number Publication date
EP1842539A1 (fr) 2007-10-10
NZ571129A (en) 2011-01-28
MX2008012867A (es) 2008-10-13
DK2004176T3 (da) 2012-02-06
JP4972156B2 (ja) 2012-07-11
US7875648B2 (en) 2011-01-25
WO2007115776A1 (fr) 2007-10-18
PL2004176T3 (pl) 2012-03-30
JP2009532404A (ja) 2009-09-10
AU2007236161A1 (en) 2007-10-18
EP2004176B1 (fr) 2011-10-26
CA2648155A1 (fr) 2007-10-18
ES2371627T3 (es) 2012-01-05
CA2648155C (fr) 2011-11-15
PT2004176E (pt) 2011-11-23
US20090176867A1 (en) 2009-07-09
AU2007236161B2 (en) 2009-12-10
EP2004176A1 (fr) 2008-12-24
CY1112132T1 (el) 2015-11-04
SI2004176T1 (sl) 2012-01-31
ATE530181T1 (de) 2011-11-15

Similar Documents

Publication Publication Date Title
IN2012DN01233A (fr)
WO2008048981A3 (fr) Antagonistes d'indole du récepteur p2y1 utiles dans le traitement d'états thrombotiques
WO2007096151A3 (fr) Composes organiques
EA201000050A1 (ru) Замещенные бициклолактамные соединения
WO2012007868A3 (fr) Composés chimiques
HK1149258A1 (en) Compounds
GB0722077D0 (en) Compounds
JO2800B1 (en) Rosaclubta tetrahydrate compounds [B] indole androgen regulators
MX2008016134A (es) Derivados de fenol para el tratamiento de enfermedades respiratorias.
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
TW200722081A (en) New therapeutic combinations for the treatment or prevention of depression
WO2008020040A3 (fr) Utilisation de composés et de dérivés de 2,5-dihydroxybenzène pour le traitement de la fibrose
TW200626158A (en) Naphthaline derivatives
TW200639156A (en) New compounds
ZA200806778B (en) N-Hydroxyacrylamide compounds
MX2009013501A (es) Compuestos piperidinicos y sus usos.
WO2006077024A3 (fr) Derives de 5-aminoindole
TNSN08369A1 (en) Benzimidazole derivatives
WO2007131907A3 (fr) Dérivés de 1h-indol-5-yl-pipérazin-1-yl-méthanone
MX2010006108A (es) Inhibidores de estearoil-coa-desaturasa.
MX2012004835A (es) Derivados de espirolactama y usos de los mismos.
WO2007111983A8 (fr) Nouvelles combinaisons thérapeutiques pour le traitement ou la prévention de troubles psychotiques
ZA200807800B (en) Use of N-(dibenz (B,F) oxepin-10-ylmethyl) N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of congenital muscular dystrophy or myopathy resulting from collagen VI deficiency
TW200800993A (en) Organic compounds
WO2008041134A3 (fr) Utilisation de derives de guanabenz de chlore dans le traitement des maladies a prions